Stock A195940 HK INNO.N CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Financials HK inno.N Corporation

Equities

A195940

KR7195940002

Pharmaceuticals

End-of-day quote Korea S.E.
Other stock markets
 03:30:00 16/05/2024 am IST 		5-day change 1st Jan Change
37,650 KRW -0.13% Intraday chart for HK inno.N Corporation -0.79% -15.30%
2022 Sebela Pharmaceuticals® Acquires Exclusive Licensing Rights from HK inno.N Corporation to Develop and Commercialize Tegoprazan in the U.S. and Canada CI
2022 Sebela Pharmaceuticals Enters an Exclusive Partnership with HK inno.N Corporation CI

Valuation

Fiscal Period: December 2021 2022 2023 2024
Capitalization 1 15,17,486 10,66,620 10,66,620 10,66,620
Enterprise Value (EV) 2 1,943 1,050 1,374 1,335
P/E ratio 53.4 x 27.6 x 22.7 x 14.6 x
Yield - 0.85% 0.85% 0.91%
Capitalization / Revenue 1.97 x 1.24 x 1.29 x 1.16 x
EV / Revenue 2.52 x 1.24 x 1.66 x 1.46 x
EV / EBITDA 23.5 x 12 x 14.3 x 9.28 x
EV / FCF 715 x 27.4 x 23.4 x 14.7 x
FCF Yield 0.14% 3.65% 4.26% 6.78%
Price to Book 1.32 x 0.92 x 0.88 x 0.84 x
Nbr of stocks (in thousands) 28,904 28,330 28,330 28,330
Reference price 3 52,500 37,650 37,650 37,650
Announcement Date 09/02/22 10/03/23 - -
1KRW in Million2KRW in Billions3KRW
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022 2023 2024
Net sales 1 598.4 769.8 846.5 827.2 917.8
EBITDA 1 - 82.57 87.37 96.09 143.9
EBIT 1 - 50.32 52.53 65.84 100.8
Operating Margin - 6.54% 6.2% 7.96% 10.98%
Earnings before Tax (EBT) 1 - 27.78 37.82 51.79 86.09
Net income 1 - 24.74 38.13 47.07 72.95
Net margin - 3.21% 4.5% 5.69% 7.95%
EPS 2 1,257 984.0 1,342 1,657 2,574
Free Cash Flow 3 - 2,720 38,262 58,600 90,590
FCF margin - 353.32% 4,519.94% 7,083.93% 9,870.5%
FCF Conversion (EBITDA) - 3,293.92% 43,794.21% 60,986.35% 62,953.24%
FCF Conversion (Net income) - 10,995.49% 1,00,335.62% 1,24,508.05% 1,24,180.95%
Dividend per Share 2 - - 320.0 320.0 342.7
Announcement Date 31/03/21 09/02/22 10/03/23 - -
1KRW in Billions2KRW3KRW in Million
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4
Net sales 1 180.2 251.9 198.2 216.3 201.8 210.6 219.9 221.6
EBITDA - - - - - - - -
EBIT 1 4.23 17.66 22.26 8.38 5.95 13.08 21.74 22.13
Operating Margin 2.35% 7.01% 11.23% 3.87% 2.95% 6.21% 9.89% 9.99%
Earnings before Tax (EBT) 1 - 15 19.12 3.1 5.2 10.27 19.27 19.4
Net income 1 - 13.48 14.96 2.292 2.9 8.125 14.2 14.76
Net margin - 5.35% 7.55% 1.06% 1.44% 3.86% 6.46% 6.66%
EPS - - - - - - - -
Dividend per Share - - - - - - - -
Announcement Date 09/05/22 02/08/22 31/10/22 10/03/23 - - - -
1KRW in Billions
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023 2024
Net Debt 1 - 426 309 307 269
Net Cash position 1 - - - - -
Leverage (Debt/EBITDA) - 5.159 x 3.201 x 3.2 x 1.868 x
Free Cash Flow 2 - 2,720 38,262 58,600 90,590
ROE (net income / shareholders' equity) - 2.64% 3.29% 3.96% 5.72%
ROA (Net income/ Total Assets) - 1.43% 2.09% 2.58% 3.94%
Assets 1 - 1,726 1,820 1,825 1,851
Book Value Per Share 3 - 39,819 40,873 42,778 44,744
Cash Flow per Share 3 - - 2,062 2,980 4,141
Capex 1 - 24.1 20.3 27.1 36.3
Capex / Sales - 3.13% 2.4% 3.28% 3.95%
Announcement Date 31/03/21 09/02/22 10/03/23 - -
1KRW in Billions2KRW in Million3KRW
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for HK inno.N Corporation

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
37,650 KRW
Average target price
53,750 KRW
Spread / Average Target
+42.76%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

1st Jan change Capi.
HK INNO.N CORPORATION Stock HK inno.N Corporation
-15.30% 79Cr
KYOWA KIRIN CO. LTD. Stock Kyowa Kirin Co. Ltd.
+11.98% 908.31Cr
SK BIOPHARMACEUTICALS CO., LTD. Stock SK Biopharmaceuticals Co., Ltd.
-10.76% 506.36Cr
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD. Stock Shenyang Xingqi Pharmaceutical Co.,Ltd.
+53.60% 485.49Cr
YUHAN CORPORATION Stock Yuhan Corporation
+7.56% 385.2Cr
INDIVIOR PLC Stock Indivior PLC
+14.09% 237.15Cr
BETTA PHARMACEUTICALS CO., LTD. Stock Betta Pharmaceuticals Co., Ltd.
-21.42% 236.42Cr
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. Stock Shanghai Shyndec Pharmaceutical Co., Ltd.
+25.03% 226.57Cr
CHANGCHUN BCHT BIOTECHNOLOGY CO. Stock Changchun BCHT Biotechnology Co.
-30.36% 222.12Cr
VELOXIS PHARMACEUTICALS A/S Stock Veloxis Pharmaceuticals A/S
-0.50% 164.41Cr
Specialty & Advanced Pharmaceuticals
  1. Stock Market
  2. Equities
  3. A195940 Stock
  4. Financials HK inno.N Corporation
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW